{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:51:15Z","timestamp":1784803875410,"version":"3.55.0"},"reference-count":26,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.3892\/or.2015.4448","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T13:40:31Z","timestamp":1448458831000},"page":"1179-1185","source":"Crossref","is-referenced-by-count":18,"title":["Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris"],"prefix":"10.3892","volume":"35","author":[{"given":"MANMAN","family":"SU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WEIQIN","family":"CHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KUN","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MANHUA","family":"CUI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHUYING","family":"WU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TIANMIN","family":"XU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,11,25]]},"reference":[{"key":"key20180107211216_b1-or-35-02-1179","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10540-006-9030-z","article-title":"Melittin: A membrane-active peptide with diverse functions","volume":"27","author":"Raghuraman","year":"2007","journal-title":"Biosci Rep"},{"key":"key20180107211216_b2-or-35-02-1179","doi-asserted-by":"crossref","first-page":"23678","DOI":"10.1074\/jbc.M112.362756","article-title":"Melittin modulates keratinocyte function through P2 receptor-dependent ADAM activation","volume":"287","author":"Sommer","year":"2012","journal-title":"J Biol Chem"},{"key":"key20180107211216_b3-or-35-02-1179","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.pharmthera.2007.04.004","article-title":"Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds","volume":"115","author":"Son","year":"2007","journal-title":"Pharmacol Ther"},{"key":"key20180107211216_b4-or-35-02-1179","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1074\/jbc.M807191200","article-title":"Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK\/p38 and inhibiting IkappaBalpha kinase-NFkappaB","volume":"284","author":"Wang","year":"2009","journal-title":"J Biol Chem"},{"key":"key20180107211216_b5-or-35-02-1179","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.taap.2011.10.009","article-title":"Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2\/STAT3 pathway","volume":"258","author":"Jo","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"key20180107211216_b6-or-35-02-1179","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/hep.22240","article-title":"Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway","volume":"47","author":"Liu","year":"2008","journal-title":"Hepatology"},{"key":"key20180107211216_b7-or-35-02-1179","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00262-003-0457-9","article-title":"Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: In vitro and in vivo studies","volume":"53","author":"Russell","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"key20180107211216_b8-or-35-02-1179","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1172\/JCI38842","article-title":"Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth","volume":"119","author":"Soman","year":"2009","journal-title":"J Clin Invest"},{"key":"key20180107211216_b9-or-35-02-1179","doi-asserted-by":"crossref","first-page":"16318","DOI":"10.1021\/la302654s","article-title":"Role of nanoparticle surface functionality in the disruption of model cell membranes","volume":"28","author":"Moghadam","year":"2012","journal-title":"Langmuir"},{"key":"key20180107211216_b10-or-35-02-1179","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1742-7843.2011.00821.x","article-title":"Production of human antibody fragments binding to melittin and phospholipase A2 in Africanised bee venom: Minimising venom toxicity","volume":"110","author":"Funayama","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"key20180107211216_b11-or-35-02-1179","first-page":"829","article-title":"In vitro- and in vivo-targeted tumor lysis by an MMP2 cleavable melittin-LAP fusion protein","volume":"35","author":"Holle","year":"2009","journal-title":"Int J Oncol"},{"key":"key20180107211216_b12-or-35-02-1179","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1158\/1541-7786.MCR-12-0349","article-title":"Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism","volume":"10","author":"Botkjaer","year":"2012","journal-title":"Mol Cancer Res"},{"key":"key20180107211216_b13-or-35-02-1179","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4014\/jmb.1305.05004","article-title":"Expression, purification, and biological characterization of the amino-terminal fragment of urokinase in Pichia pastoris","volume":"23","author":"Li","year":"2013","journal-title":"J Microbiol Biotechnol"},{"key":"key20180107211216_b14-or-35-02-1179","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7150\/thno.7409","article-title":"uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection","volume":"4","author":"Yang","year":"2013","journal-title":"Theranostics"},{"key":"key20180107211216_b15-or-35-02-1179","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2047-783X-18-28","article-title":"Clinical significance of the uPA system in gastric cancer with peritoneal metastasis","volume":"18","author":"Ding","year":"2013","journal-title":"Eur J Med Res"},{"key":"key20180107211216_b16-or-35-02-1179","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3748\/wjg.v18.i3.244","article-title":"High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis","volume":"18","author":"Thummarati","year":"2012","journal-title":"World J Gastroenterol"},{"key":"key20180107211216_b17-or-35-02-1179","first-page":"636","article-title":"The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients","volume":"60","author":"Foekens","year":"2000","journal-title":"Cancer Res"},{"key":"key20180107211216_b18-or-35-02-1179","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1471-2407-6-211","article-title":"Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer","volume":"6","author":"Kim","year":"2006","journal-title":"BMC Cancer"},{"key":"key20180107211216_b19-or-35-02-1179","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.4161\/cc.5.16.2994","article-title":"Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation\/dormancy, clinical outcome and minimal residual disease","volume":"5","author":"Laufs","year":"2006","journal-title":"Cell Cycle"},{"key":"key20180107211216_b20-or-35-02-1179","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.2174\/1381612023392676","article-title":"Inhibitors of the protease domain of urokinase-type plasminogen activator","volume":"8","author":"Rockway","year":"2002","journal-title":"Curr Pharm Des"},{"key":"key20180107211216_b21-or-35-02-1179","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2174\/138161211796718143","article-title":"The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling","volume":"17","author":"Carriero","year":"2011","journal-title":"Curr Pharm Des"},{"key":"key20180107211216_b22-or-35-02-1179","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/hum.2005.16.1157","article-title":"Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: Respective contribution of the urokinase plasminogen activator receptor-dependent or-independent pathway","volume":"16","author":"Li","year":"2005","journal-title":"Hum Gene Ther"},{"key":"key20180107211216_b23-or-35-02-1179","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10555-012-9383-7","article-title":"Ovarian cancer molecular pathology","volume":"31","author":"Longuesp\u00e9e","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"key20180107211216_b24-or-35-02-1179","first-page":"242","article-title":"ADP-ribosylation factor-like 4C (ARL4C), a novel ovarian cancer metastasis suppressor, identified by integrated genomics","volume":"7","author":"Su","year":"2015","journal-title":"Am J Transl Res"},{"key":"key20180107211216_b25-or-35-02-1179","first-page":"73","article-title":"A view on dendritic cell immunotherapy in ovarian cancer: How far have we come?","volume":"7","author":"Coosemans","year":"2015","journal-title":"Facts Views Vis Obgyn"},{"key":"key20180107211216_b26-or-35-02-1179","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/toxins7020423","article-title":"The anti-cancer potency and mechanism of a novel tumor-activated fused toxin, DLM","volume":"7","author":"Sun","year":"2015","journal-title":"Toxins"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2015.4448\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T21:12:30Z","timestamp":1515359550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2015.4448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,25]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,11,25]]},"published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.3892\/or.2015.4448"],"URL":"https:\/\/doi.org\/10.3892\/or.2015.4448","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,25]]}}}